AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

Betsy Goodfellow | September 11, 2023 | News story | Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial 

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s (trastuzumab deruxtecan) continued strong and durable tumour responses in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).

The drug has been developed collaboratively between AstraZeneca and Daiichi Sankyo.

The results were presented at the International Association for the Study of Lung Cancer (ASLC) 2023 World Conference on Lung Cancer (WCLC) as well as being published in the Journal of Clinical Oncology.

This analysis confirmed the objective response rate (ORR) as 49% and 56% in the 5.4mg/kg and 6.4mg/kg dosing groups respectively. The safety profile remains consistent with the established profile of the drug, however the 5.4mg/kg dose demonstrated a favourable safety profile for this indication.

Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, commented: “These results from DESTINY-Lung02 highlight that HER2 is an actionable target in lung cancer and reinforce the importance of testing for predictive biomarkers, including HER2 alterations, at the time of diagnosis to accurately identify patients who may be able to benefit from a targeted treatment. The data also reaffirm our belief in Enhertu as a potential new targeted treatment option for patients who have historically had limited options.”

Ken Takeshita, global head of R&D at Daiichi Sankyo, added: “The disease control achieved by more than 90% of patients with previously treated HER2-mutant non-small cell lung cancer in the primary analysis of DESTINY-Lung02 reinforces the efficacy we have already seen with Enhertu in this hard-to-treat disease. These results, along with encouraging progression-free survival and overall survival findings reported for the first time, demonstrate the potential role of Enhertu as an important treatment option for this patient population.”

Betsy Goodfellow

Related Content

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human …

Latest content